Cytopenias during Treatment of HIV–HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study

Abstract

Background

Until recently, recommendations for HCV treatment in HIV-coinfected patients have been combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). However, this treatment is often accompanied with cytopenias which lead to drug-dose reduction/discontinuation, therefore influencing sustained virological response (SVR). This study aimed at evaluating incidence and predictors of cytopenias and to define their impact on SVR in Italian HIV–HCV-coinfected patients undergoing PEG-IFN/RBV treatment.

Methods

OPERA was a multicentric, observational study conducted in 98 Italian centres. Patients with HIV–HCV coinfection were administered with PEG-IFN/RBV combination treatment for 48 weeks. Incidence and time of onset of cytopenias and multiple bone marrow toxicity (mBMT) was monitored. Logistic regression analysis assessed factors associated with SVR, anaemia, neutropenia, thrombocytopenia and mBMT.

Results

Between 2005 and 2011, 1,523 patients were enrolled. Anaemia (haemoglobin <10 g/dl) occurred in 197 (12.9%) patients and a haemoglobin drop ≥3 g/dl was recorded in 796 (52.3%). Anaemia did not impact on SVR, its rate being 42.1% and 38.1%, respectively, in patients with and without anaemia (P=0.31). Therapy discontinuation due to anaemia occurred in 47 patients (3.1%). Neutropenia (<1,000 neutrophils/mm³) occurred in 652 (42.8%) patients, and SVR was higher (P<0.001) for patients with neutropenia (44.8%) compared to without neutropenia (34%). Patients developing neutropenia did not have an increased risk of developing infections. Thrombocytopenia (<100,000 platelets/mm³) occurred in 595 (39.1%) patients, SVR was not influenced by it (38.2% versus 38.9% in patients with and without thrombocytopenia, respectively; P=0.79), and 16 patients (1.1%) discontinued therapy due to it. Cirrhosis was found in 148/734 evaluated patients (20.2%) and was significantly associated with thrombocytopenia (P<0.0001). mBMT was found in 417 patients (27.4%).

Conclusions

Cytopenias are frequent side effects of PEG-IFN/RBV combination therapy in HIV–HCV-coinfected patients. However, SVR is not negatively affected by their presence, nor is there an increased risk of infections in patients developing neutropenia. Several predicting factors for the onset of cytopenias have been unravelled, which will help to identify early those patients at high risk of developing cytopenia.

References

Andreoni

, Giacometti

, Maida

, Meraviglia

, Ripamonti

, Sarmati

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.

Eur Rev Med Pharmacol Sci 2012; 16: 1473–1483.

Hernandez

M.D.

, Sherman

K.E.

HIV/hepatitis C coinfection natural history and disease progression.

Curr Opin HIV AIDS 2011; 6: 478–482.

Carrat

, Bani-Sadr

, Pol

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

JAMA 2004; 292: 2839–2848.

Núñez

, Miralles

, Berdún

M.A.

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.

AIDS Res Hum Retroviruses 2007; 23: 972–982.

Torriani

F.J.

, Rodriguez-Torres

, Rockstroh

J.K.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

N Engl J Med 2004; 351: 438–450.

De Franceschi

, Fattovich

, Turrini

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Hepatology 2000; 31: 997–1004.

Mauss

Treatment of viral hepatitis in HIV-coinfected patients–adverse events and their management.

J Hepatol 2006; 44: S114–S118.

Butt

A.A.

, Umbleja

, Andersen

J.W.

, Chung

R.T.

, Sherman

K.E.

The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.

Aliment Pharmacol Ther 2011; 33: 1234–1244.

Alvarez

, Dieterich

D.T.

, Brau

, Moorehead

, Ball

, Sulkowski

M.S.

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.

J Viral Hepat 2006; 13: 683–689.

10.

Opravil

, Sasadeusz

, Cooper

D.A.

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.

J Acquir Immune Defic Syndr 2008; 47: 36–49.

11.

Moreno

, Quereda

, Moreno

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

AIDS 2004; 18: 67–73.

12.

Laguno

, Cifuentes

, Murillas

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.

Hepatology 2009; 49: 22–31.

13.

Crespo

, Sauleda

, Esteban

J.I.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

J Viral Hepat 2007; 14: 228–238.

14.

Medeiros

B.C.

, Seligman

P.A.

, Everson

G.T.

, Forman

L.M.

Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C.

J Clin Gastroenterol 2004; 38: 84–86.

15.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

N Engl J Med 2002; 347: 975–982.

16.

Heathcote

E.J.

, Shiffman

M.L.

, Cooksley

W.G.

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

N Engl J Med 2000; 343: 1673–1680.

17.

Carosi

, Bruno

, Cariti

OPERA: use of pegylated interferon plus ribavirin for treating hepatitis C/HIV co-infection in interferon-naïve patients.

Antivir Ther 2014; doi: 10.3851/IMP2757.

18.

Bani-Sadr

, Goderel

, Penalba

Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.

J Viral Hepat 2007; 14: 639–644.

19.

Naggie

, Rallon

N.I.

, Benito

J.M.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.

J Infect Dis 2012; 205: 376–383.

20.

Osinusi

, Naggie

, Poonia

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

J Med Virol 2012; 84: 1106–1114.

21.

Domingo

, Guardiola

J.M.

, Salazar

Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.

Antimicrob Agents Chemother 2012; 56: 2987–2993.

22.

Núñez

, Ocampo

, Aguirrebengoa

Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

J Viral Hepat 2008; 15: 363–369.

23.

Teuber

, Mauss

, Hueppe

Hemoglobin decline >2 g/dl during peginterferon alfa-2b (peg-2b)/ ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infection without erythropoietin use.

AASLD. 9–13 November 2012, Boston, MA, USA. Abstract 789.

24.

Teuber

, Mauss

, Hüppe

Hemoglobine decline during peginterferon alfa-2b / ribavirin treatment in real-life is associated with favorable SVR rates in difficult-to-treat patients with HCV genotype 1 infection.

EASL. 18–22 April 2012, Barcelona, Spain. Poster 1164.

25.

Sievert

, Dore

G.J.

, McCaughan

G.W.

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.

Hepatology 2011; 53: 1109–1117.

26.

McHutchison

J.G.

, Manns

, Patel

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Gastroenterology 2002; 123: 1061–1069.

27.

Everson

G.T.

, Hoefs

J.C.

, Seeff

L.B.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial.

Hepatology 2006; 44: 1675–1684.

28.

Shiffman

M.L.

, Salvatore

, Hubbard

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.

Hepatology 2007; 46: 371–379.

29.

Sulkowski

M.S.

, Shiffman

M.L.

, Afdhal

N.H.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Gastroenterology 2010; 139: 1602–1611.

30.

Behler

C.M.

, Vittinghoff

, Lin

Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.

Clin Infect Dis 2007; 44: 1375–1383.

31.

Mira

J.A.

, López-Cortés

L.F.

, Merino

Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.

Antivir Ther 2007; 12: 1225–1235.

32.

Rotman

, Katz

, Cohen

Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.

J Viral Hepat 2009; 16: 340–345.

33.

Nachnani

J.S.

, Rao

G.A.

, Bulchandani

, Pandya

P.K.

, Alba

L.M.

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.

Ann Hematol 2010; 89: 121–125.

34.

Talal

A.H.

, Liu

R-C

, Zeremski

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

J Acquir Immune Defic Syndr 2011; 58: 261–268.

35.

Koskinas

, Zacharakis

, Sidiropoulos

Granulocyte colony stimulating factor in HCV genotype-1 patients who develop PEG-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.

J Med Virol 2009; 81: 848–852.

36.

Tandon

, Doucette

, Fassbender

, Vandermeer

, Durec

, Dryden

D.M.

Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.

J Viral Hepat 2011; 18: e381–e393.

37.

Soza

, Everhart

J.E.

, Ghany

M.G.

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

Hepatology 2002; 36: 1273–1279.

38.

Puoti

, Babudieri

, Rezza

Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?

Antivir Ther 2004; 9: 627–630.

39.

Cooper

C.L.

, Al-Bedwawi

, Lee

, Garber

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia.

Clin Infect Dis 2006; 42: 1674–1678.

40.

Roomer

, Hansen

B.E.

, Janssen

H.L.A.

, de Knegt

R.J.

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Hepatology 2010; 52: 1225–1231.

41.

Cooper

C.L.

, Al-Bedwawi

Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia.

HIV Clin Trials 2006; 7: 251–254.

42.

Payer

B.A.

, Reiberger

, Breitenecker

The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.

J Infect 2012; 65: 142–149.

43.

Soriano

, Miralles

, Berdún

M.A.

Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.

Antivir Ther 2007; 12: 469–476.

44.

Cargnel

, Angeli

, Mainini

Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Antivir Ther 2005; 10: 309–317.

45.

Tanaka

, Kurosaki

, Nishida

Genome-wide association study identified ITPA/DDRGK1 variants refecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.

Hum Mol Genet 2011; 20: 3507–3516.

46.

Dusheiko

, Afdhal

, Giannini

Results of enable 2, a Phase 3, multicenter study of eltrombopag and peginterferon alfa-2b treatment in patients with hepatitis c and thrombocytopenia.

EASL. 18–22 April 2012, Barcelona, Spain. Abstract 279.

47.

Slim

, Mildvan

, Han

, Korner

The association of cytopenias (anemia, neutropenia, lymphopenia, and thrombocytopenia) with virologic response in HIV/HCV co-infected patients treated with pegylated interferon alfa-2a (Peg-IFN2a) and ribavirin (RBV).

AASLD. 9–13 November 2012, Boston, MA, USA. Abstract 1758.

48.

Henry

D.H.

, Slim

, Lamarca

, Bowers

, Leitz

Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.

AIDS Res Hum Retroviruses 2007; 23: 1–9.